Roll over image to zoom in
CA ATRA-IO（Vesanoid）Tretinoin 10mg online
$399.00
Status: In stock
Indicated for the induction of remission in patients with acute promyelocytic leukaemia, FAB classification M3, including the M3 variant, who are refractory to or have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated. It is for the induction of remission only, and patients should receive an accepted form of remission consolidation and/or maintenance therapy afterwards.
CA ATRA-IO also known as Indian Generic Vesanoid(Tretinoin), is indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated. Tretinoin is for the induction of remission only. The optimal consolidation or maintenance regimens have not been defined, but all patients should receive an accepted form of remission consolidation and/or maintenance therapy for APL after completion of induction therapy with Tretinoin.
CONTRAINDICATIONS
Tretinoin is contraindicated in patients with a known hypersensitivity to Tretinoin, any of its components, or other retinoids. Tretinoin should not be given to patients who are sensitive to parabens, which are used as preservatives in the gelatin capsule
ADVERSE REACTIONS
Virtually all patients experience some drug-related toxicity, especially headache, fever, weakness, and fatigue. These adverse effects are seldom permanent or irreversible nor do they usually require interruption of therapy. Some of the adverse events are common in patients with APL, including hemorrhage, infections, gastrointestinal hemorrhage, disseminated intravascular coagulation, pneumonia, septicemia, and cerebral hemorrhage. The following describes the adverse events, regardless of drug relationship, that were observed in patients treated with Tretinoin.
CA ATRA-IO’s brand name in usa is Vesanoid by Roche. CA ATRA-IO is a generic prescription medicine from Jenome Biophar, which is one of the biggest pharmaceutical company in India.
CONTRAINDICATIONS
Tretinoin is contraindicated in patients with a known hypersensitivity to Tretinoin, any of its components, or other retinoids. Tretinoin should not be given to patients who are sensitive to parabens, which are used as preservatives in the gelatin capsule
ADVERSE REACTIONS
Virtually all patients experience some drug-related toxicity, especially headache, fever, weakness, and fatigue. These adverse effects are seldom permanent or irreversible nor do they usually require interruption of therapy. Some of the adverse events are common in patients with APL, including hemorrhage, infections, gastrointestinal hemorrhage, disseminated intravascular coagulation, pneumonia, septicemia, and cerebral hemorrhage. The following describes the adverse events, regardless of drug relationship, that were observed in patients treated with Tretinoin.
CA ATRA-IO’s brand name in usa is Vesanoid by Roche. CA ATRA-IO is a generic prescription medicine from Jenome Biophar, which is one of the biggest pharmaceutical company in India.
Related products
Recently Viewed Products
